171 related articles for article (PubMed ID: 31164324)
1. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.
Kristensen G; Røder MA; Berg KD; Elversang J; Iglesias-Gato D; Moreira J; Toft BG; Brasso K
APMIS; 2018 Oct; 126(10):804-813. PubMed ID: 30191621
[TBL] [Abstract][Full Text] [Related]
3. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
5. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
7. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
8. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
9. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
Massoner P; Kugler KG; Unterberger K; Kuner R; Mueller LA; Fälth M; Schäfer G; Seifarth C; Ecker S; Verdorfer I; Graber A; Sültmann H; Klocker H
PLoS One; 2013; 8(2):e55207. PubMed ID: 23390522
[TBL] [Abstract][Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
11. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
12. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
13. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
14. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
15. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
17. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
19. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract][Full Text] [Related]
20. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.
Weiner AB; Faisal FA; Davicioni E; Karnes RJ; Griend DJV; Lotan TL; Schaeffer EM
Eur Urol Oncol; 2021 Dec; 4(6):955-962. PubMed ID: 32540218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
